Solventum (SOLV)

Healthcare · Medical Instruments & Supplies · S&P 500
$87.04 -1.12% on the day Market cap $15.4B 52-week range $62.38 to $94.16 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Solventum's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

C

Five factors scored 1 to 9 from SOLV's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation7
Profitability7
Growth4
Financial health3
Cash efficiency0

Key numbers

P/E (trailing)10.9x
P/E (forward)13.6x
Price / free cash flow—
EV / EBITDA9.15x
Price / sales1.86x
Price / book3.10x
Revenue growth+2.2%
Operating margin25.0%
Net margin17.3%
Return on equity29.9%
Dividend yield—
Debt / equity1.97x

Results from SEC filings

Fiscal years, from Solventum's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year2022202320242025
Revenue$8.1B$8.2B$8.3B$8.3B
Net income$1.3B$1.3B$479M$1.6B
Free cash flow$1.4B$1.6B$805M-$10M
EPS (diluted)$7.78$7.79$2.76$8.88
Operating margin20.8%20.6%12.6%26.2%

Where the revenue comes from

Revenue by segments, fiscal 2025.

MedSurg$4.8B60%
Health Information Systems$1.4B17%
Dental Solutions$1.3B17%
Purification and Filtration$497M6%

Superinvestors who own SOLV

From each investor's latest 13F filing (what a 13F shows). 6 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Ric Dillon
Diamond Hill Capital Management
Trimmed $150M1.2%Q2 2026
Cliff Asness
AQR Capital Management
Added $83M0.03%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $59M0.14%Q2 2026
Richard Pzena
Pzena Investment Management
Trimmed $32M0.10%Q2 2026
Mario Gabelli
GAMCO Investors
Added $903,2720.01%Q2 2026
Hersh Cohen
ClearBridge Investments
Added $295,3300.0%Q2 2026

Insider buying

Open-market purchases by Solventum's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Mar 10, 2026 Amy Mcbride Wendell
1,475$68.03$100,344

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when SOLV trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Solventum insiders buying the stock?

1 open-market insider purchase of SOLV in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Solventum?

6 of the superinvestors Investingly tracks hold SOLV in their latest 13F, including Ric Dillon, Cliff Asness, Joel Greenblatt.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.